Cargando…
Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial hypertension (PAH), chronic thromboembolic PH (g...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012471/ https://www.ncbi.nlm.nih.gov/pubmed/29671674 http://dx.doi.org/10.1177/2045894018775056 |
_version_ | 1783333933638746112 |
---|---|
author | Chebib, Nader Mornex, Jean-François Traclet, Julie Philit, François Khouatra, Chahera Zeghmar, Sabrina Turquier, Ségolène Cottin, Vincent |
author_facet | Chebib, Nader Mornex, Jean-François Traclet, Julie Philit, François Khouatra, Chahera Zeghmar, Sabrina Turquier, Ségolène Cottin, Vincent |
author_sort | Chebib, Nader |
collection | PubMed |
description | Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial hypertension (PAH), chronic thromboembolic PH (group 4), and group 5 PH. We retrospectively analyzed consecutive incident PH patients in a single center between January 2006 and November 2014. Data were acquired from a prospective database. Clinical, functional, and hemodynamic characteristics, as well as survival, were compared between the four groups of precapillary PH. A total of 363 patients were analyzed; 164 patients (45.2%) belonged to group 1 PAH, 109 (30%) to group 3 PH, 65 (17.9%) to group 4 PH, and 25 (6.9%) to group 5 PH. Group 3 patients were predominantly male and were more frequently in New York Heart Association (NYHA) class III/IV. Patients with group 3 and 4 PH were older, had significantly lower 6-min walking distance (6MWD), higher mean pulmonary arterial pressure, higher pulmonary vascular resistance (PVR), and lower cardiac index (CI) than PAH patients. Group 3 and 5 patients had significantly lower total lung capacity (TLC), forced vital capacity (FVC), and FEV1; group 3 patients had the lowest carbon monoxide transfer coefficient values. PH therapy was used in 90.9% of group 3 patients. Univariate analysis of prognostic factors in the overall population showed that age, male gender, NYHA class, groups 3 and 4 PH (vs. PAH), 6MWD, FVC, TLC, carbon monoxide transfer coefficient (KCO), PVR, CI, and venous oxygen saturation were significantly associated with greater mortality. Multivariate analysis showed that age, PH group 4, 6MWD, and KCO but no longer PH group 3 were significantly associated with mortality. Patients with group 3 PH are older, have more severe baseline presentation and lower survival rates than PAH patients in univariate analysis, that seemed to be related to older age. |
format | Online Article Text |
id | pubmed-6012471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-60124712018-07-05 Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups Chebib, Nader Mornex, Jean-François Traclet, Julie Philit, François Khouatra, Chahera Zeghmar, Sabrina Turquier, Ségolène Cottin, Vincent Pulm Circ Research Article Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial hypertension (PAH), chronic thromboembolic PH (group 4), and group 5 PH. We retrospectively analyzed consecutive incident PH patients in a single center between January 2006 and November 2014. Data were acquired from a prospective database. Clinical, functional, and hemodynamic characteristics, as well as survival, were compared between the four groups of precapillary PH. A total of 363 patients were analyzed; 164 patients (45.2%) belonged to group 1 PAH, 109 (30%) to group 3 PH, 65 (17.9%) to group 4 PH, and 25 (6.9%) to group 5 PH. Group 3 patients were predominantly male and were more frequently in New York Heart Association (NYHA) class III/IV. Patients with group 3 and 4 PH were older, had significantly lower 6-min walking distance (6MWD), higher mean pulmonary arterial pressure, higher pulmonary vascular resistance (PVR), and lower cardiac index (CI) than PAH patients. Group 3 and 5 patients had significantly lower total lung capacity (TLC), forced vital capacity (FVC), and FEV1; group 3 patients had the lowest carbon monoxide transfer coefficient values. PH therapy was used in 90.9% of group 3 patients. Univariate analysis of prognostic factors in the overall population showed that age, male gender, NYHA class, groups 3 and 4 PH (vs. PAH), 6MWD, FVC, TLC, carbon monoxide transfer coefficient (KCO), PVR, CI, and venous oxygen saturation were significantly associated with greater mortality. Multivariate analysis showed that age, PH group 4, 6MWD, and KCO but no longer PH group 3 were significantly associated with mortality. Patients with group 3 PH are older, have more severe baseline presentation and lower survival rates than PAH patients in univariate analysis, that seemed to be related to older age. SAGE Publications 2018-04-05 /pmc/articles/PMC6012471/ /pubmed/29671674 http://dx.doi.org/10.1177/2045894018775056 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Article Chebib, Nader Mornex, Jean-François Traclet, Julie Philit, François Khouatra, Chahera Zeghmar, Sabrina Turquier, Ségolène Cottin, Vincent Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups |
title | Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups |
title_full | Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups |
title_fullStr | Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups |
title_full_unstemmed | Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups |
title_short | Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups |
title_sort | pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012471/ https://www.ncbi.nlm.nih.gov/pubmed/29671674 http://dx.doi.org/10.1177/2045894018775056 |
work_keys_str_mv | AT chebibnader pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups AT mornexjeanfrancois pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups AT tracletjulie pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups AT philitfrancois pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups AT khouatrachahera pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups AT zeghmarsabrina pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups AT turquiersegolene pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups AT cottinvincent pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups |